Why the study?
Optimal thromboprophylaxis management in patients with Fontan circulation remains unclear and clinical consensus is elusive despite high thromboembolic risk and morbidity.
This perspective describes the nature of thromboembolism post-Fontan surgery and reviews evidence for current and emerging thromboprophylaxis options.
Answers are grounded in this paper and cite their sources.
Reviews post-Fontan thromboembolism risks; leaves optimal thromboprophylaxis strategies open for prospective trials.
The Fontan circulation introduces an increased risk of thromboembolism which is associated with substantial mortality and morbidity. Adverse outcomes of thromboembolic complications post-Fontan surgery vary in both nature and severity, ranging from local tissue infarction and pulmonary embolism to Fontan failure and ischemic stroke. Furthermore, recent studies have identified that subclinical stroke is common yet underdiagnosed in Fontan patients. Fontan patients are commonly treated with antiplatelet agents and/or anticoagulants as primary thromboprophylaxis. Optimal thromboprophylaxis management in the Fontan population is still unclear, and clinical consensus remains elusive despite the growing literature on the subject. This perspective will describe the nature of thromboembolism post-Fontan surgery and provide evidence for the use of both current and emerging thromboprophylaxis options for children and adults living with Fontan circulation.
No takes yet. Share an insight, caveat, or question.
Helm et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: